Candel Therapeutics (CADL)
Market Price (3/18/2026): $5.24 | Market Cap: $287.8 MilSector: Health Care | Industry: Biotechnology
Candel Therapeutics (CADL)
Market Price (3/18/2026): $5.24Market Cap: $287.8 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -25% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Gene Editing & Therapy, Show more. | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -48 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -18% | |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 24% | |
| Key risksCADL key risks include [1] its critical dependence on the clinical trial success and regulatory approval of its lead candidate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -25% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Gene Editing & Therapy, Show more. |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -48 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -18% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 24% |
| Key risksCADL key risks include [1] its critical dependence on the clinical trial success and regulatory approval of its lead candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Candel Therapeutics (CADL) stock has gained about 10% since 11/30/2025 because of the following key factors:
1. Candel Therapeutics significantly strengthened its financial position and extended its operational runway into the first quarter of 2028. This was achieved through a follow-on equity offering in February 2026 that generated $93.5 million in net proceeds, combined with $119.7 million in cash and cash equivalents as of December 31, 2025, and access to a $130 million term loan facility, with $50 million already drawn.
2. The company announced significant advancements for its lead oncology candidate, aglatimagene besadenovec (CAN-2409). Candel Therapeutics plans to submit a Biologics License Application (BLA) for CAN-2409 in localized, intermediate-to high-risk prostate cancer in the fourth quarter of 2026. Additionally, a pivotal Phase 3 clinical trial of CAN-2409 in non-small cell lung cancer (NSCLC) is scheduled to commence in the second quarter of 2026.
Show more
1. Candel Therapeutics significantly strengthened its financial position and extended its operational runway into the first quarter of 2028. This was achieved through a follow-on equity offering in February 2026 that generated $93.5 million in net proceeds, combined with $119.7 million in cash and cash equivalents as of December 31, 2025, and access to a $130 million term loan facility, with $50 million already drawn.
2. The company announced significant advancements for its lead oncology candidate, aglatimagene besadenovec (CAN-2409). Candel Therapeutics plans to submit a Biologics License Application (BLA) for CAN-2409 in localized, intermediate-to high-risk prostate cancer in the fourth quarter of 2026. Additionally, a pivotal Phase 3 clinical trial of CAN-2409 in non-small cell lung cancer (NSCLC) is scheduled to commence in the second quarter of 2026.
Show more
Stock Movement Drivers
Fundamental Drivers
The 8.4% change in CADL stock from 11/30/2025 to 3/17/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 11302025 | 3172026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.77 | 5.17 | 8.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 55 | 55 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
11/30/2025 to 3/17/2026| Return | Correlation | |
|---|---|---|
| CADL | 8.4% | |
| Market (SPY) | -1.8% | 40.6% |
| Sector (XLV) | -5.1% | 25.4% |
Fundamental Drivers
The -10.7% change in CADL stock from 8/31/2025 to 3/17/2026 was primarily driven by a -6.2% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 8312025 | 3172026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.79 | 5.17 | -10.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 51 | 55 | -6.2% |
| Cumulative Contribution | 0.0% |
Market Drivers
8/31/2025 to 3/17/2026| Return | Correlation | |
|---|---|---|
| CADL | -10.7% | |
| Market (SPY) | 4.3% | 34.5% |
| Sector (XLV) | 9.4% | 22.3% |
Fundamental Drivers
The -42.4% change in CADL stock from 2/28/2025 to 3/17/2026 was primarily driven by a -41.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282025 | 3172026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.97 | 5.17 | -42.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 32 | 55 | -41.7% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2025 to 3/17/2026| Return | Correlation | |
|---|---|---|
| CADL | -42.4% | |
| Market (SPY) | 13.9% | 48.9% |
| Sector (XLV) | 1.8% | 34.8% |
Fundamental Drivers
The 187.2% change in CADL stock from 2/28/2023 to 3/17/2026 was primarily driven by a 9.2233720368547763E17% change in the company's P/S Multiple.| (LTM values as of) | 2282023 | 3172026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.80 | 5.17 | 187.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | |
| P/S Multiple | 419.4 | ∞ | 9.2233720368547763E17% |
| Shares Outstanding (Mil) | 29 | 55 | -47.4% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2023 to 3/17/2026| Return | Correlation | |
|---|---|---|
| CADL | 187.2% | |
| Market (SPY) | 75.6% | 7.3% |
| Sector (XLV) | 23.1% | 1.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CADL Return | 12% | -77% | -18% | 490% | -35% | -12% | -29% |
| Peers Return | -33% | -22% | 9% | -36% | 3% | 0% | -62% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -2% | 78% |
Monthly Win Rates [3] | |||||||
| CADL Win Rate | 67% | 33% | 33% | 50% | 42% | 33% | |
| Peers Win Rate | 25% | 36% | 40% | 38% | 45% | 53% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| CADL Max Drawdown | -18% | -81% | -62% | -18% | -49% | -17% | |
| Peers Max Drawdown | -35% | -58% | -33% | -59% | -58% | -20% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -3% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: REPL, CGON, TOVX, GNLX, ONCY.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/17/2026 (YTD)
How Low Can It Go
| Event | CADL | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -94.3% | -25.4% |
| % Gain to Breakeven | 1662.7% | 34.1% |
| Time to Breakeven | 194 days | 464 days |
Compare to REPL, CGON, TOVX, GNLX, ONCY
In The Past
Candel Therapeutics's stock fell -94.3% during the 2022 Inflation Shock from a high on 10/26/2021. A -94.3% loss requires a 1662.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Candel Therapeutics (CADL)
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
AI Analysis | Feedback
Here are 1-3 brief analogies for Candel Therapeutics (CADL):
- Moderna for cancer immunotherapies.
- A clinical-stage biotech aiming to be the next Vertex Pharmaceuticals, but solely focused on developing novel cancer immunotherapies.
AI Analysis | Feedback
Candel Therapeutics' major product candidates are:
- CAN-2409: An immunotherapy being developed for the treatment of pancreatic, prostate, lung cancer, and high-grade glioma.
- CAN-3110: An immunotherapy in early-stage clinical trials for the treatment of recurrent glioblastoma.
AI Analysis | Feedback
Candel Therapeutics, Inc. (CADL) is a clinical-stage biopharmaceutical company focused on the development of immunotherapies for cancer patients. As such, its product candidates (CAN-2409 and CAN-3110) are currently in various stages of clinical trials (Phase I, II, and III).
At this stage of development, Candel Therapeutics does not have major customers in the traditional sense of selling approved products or services to other companies or individuals. The company's primary activities involve research, development, and conducting clinical trials to gather data for regulatory approval. Revenues for such companies typically come from equity financing, grants, or potential collaboration agreements, rather than product sales to customers.
AI Analysis | Feedback
Paul Peter Tak, M.D., Ph.D., FMedSci President & Chief Executive Officer Dr. Paul Peter Tak has served as President and Chief Executive Officer of Candel Therapeutics and as a board member since September 2020, during which he oversaw the company's IPO process on Nasdaq in 2021. He previously held the position of President and CEO of Tempero Pharmaceuticals, which was later acquired by GlaxoSmithKline (GSK). From 2018 to 2020, Dr. Tak was a venture partner at Flagship Pioneering and also served as President and CEO of Kintai Therapeutics, a company that subsequently merged with Senda Biosciences. His extensive career includes serving as Senior Vice President, Chief Immunology Officer, and Global Development Leader at GSK from 2011 to 2018. He has also been a board director for Galvani Bioelectronics, ViiV Healthcare, and Omega Therapeutics and currently serves on the Board of Sitryx Therapeutics (which he co-founded) and Levicept, in addition to being the Chair of the Board of Citryll. Charles Schoch Chief Financial Officer Charles Schoch was appointed permanent Chief Financial Officer of Candel Therapeutics effective June 23, 2025, after serving as interim CFO since January 2024. He joined Candel in November 2021, holding various financial reporting and accounting roles, including VP of Finance and Corporate Controller. As interim CFO, he played a crucial role in leading a capital raise that generated approximately $86 million in net proceeds for the company following positive Phase 3 clinical trial results. Prior to joining Candel, Mr. Schoch was the Corporate Controller at Corbus Pharmaceuticals from 2019 to 2021. He also spent seven years at PwC's Health Industry assurance practice, where he audited a diverse range of life sciences clients, including pre-IPO and multinational public companies. Earlier in his career, he worked as a financial and operational consultant for several Third Rock Venture portfolio companies, indicating experience with companies backed by private equity firms. Francesca Barone, M.D., Ph.D. Chief Scientific Officer Dr. Francesca Barone oversees the research and development of Candel Therapeutics' proprietary enLIGHTEN™ Discovery Platform. W. Garrett Nichols, M.D., M.S. Chief Medical Officer Dr. W. Garrett Nichols was named Chief Medical Officer of Candel Therapeutics on September 7, 2022. He brings extensive biopharmaceutical experience to the company. Seshu Tyagarajan, Ph.D., RAC Chief Technical and Development Officer Dr. Seshu Tyagarajan is a member of Candel Therapeutics' leadership team.AI Analysis | Feedback
Candel Therapeutics (CADL), as a clinical-stage biopharmaceutical company, faces inherent risks primarily related to the development and commercialization of its product candidates.Key Risks to the Business
- Clinical Trial and Regulatory Risk: The primary risk to Candel Therapeutics stems from the uncertainty of successfully completing clinical trials and obtaining regulatory approvals for its drug candidates. The company's lead candidates, CAN-2409 and CAN-3110, are in various stages of clinical development, including Phase II and Phase III trials. Despite positive interim or topline data, the success rate for drugs advancing from clinical trials to market approval is low, typically less than 12%. Even if clinical trials demonstrate efficacy and safety, there is no guarantee of FDA approval, and the regulatory process itself is complex and lengthy. Furthermore, even with approval, there remains a risk related to the effective execution of the commercial launch and market acceptance of these novel oncolytic viral immunotherapies.
- Financial Risk and Capital Dependence: As a clinical-stage company, Candel Therapeutics currently generates no revenue and operates at a net loss, relying heavily on external funding to finance its research and development activities and other operations. While the company has secured financing, including a term loan facility, to extend its cash runway, it continues to incur significant operating losses driven by rising R&D expenses. Future capital raises may be necessary, and there is a risk that such funding may not be available on favorable terms, or at all. Additionally, restrictive covenants in debt agreements could limit the company's financial and operational flexibility and increase the risk of default.
- Market Acceptance and Commercialization Risk: Even upon successful regulatory approval, Candel Therapeutics' products face the risk of not achieving significant market acceptance or generating substantial sales. The biopharmaceutical market is highly competitive, and Candel's viral-based immunotherapy approach may face skepticism or challenges in widespread adoption by healthcare providers and patients. For instance, while CAN-2409 has shown promising results in prostate cancer, questions remain regarding its differentiation and value proposition given existing treatment options. Pricing pressures and the need to demonstrate compelling value to justify the cost of novel therapies also pose significant commercialization challenges.
AI Analysis | Feedback
null
AI Analysis | Feedback
Candel Therapeutics (symbol: CADL) focuses on developing immunotherapies for various cancers. The addressable markets for its main product candidates are outlined below:
| Product/Service | Disease | Addressable Market Size | Region |
|---|---|---|---|
| CAN-2409 | Pancreatic Cancer | USD 3.25 billion (in 2025) | Global |
| CAN-2409 | Prostate Cancer | USD 17.0 billion (in 2024) | Global |
| CAN-2409 | Lung Cancer | USD 35.1 billion (in 2024) | Global |
| CAN-2409 | High-Grade Glioma | ~USD 830 million (in 2023) | 7 Major Markets (US, EU4, UK, Japan) |
| CAN-3110 | Recurrent Glioblastoma | USD 380.6 million (in 2025) | Global |
AI Analysis | Feedback
Candel Therapeutics (CADL), a clinical-stage biopharmaceutical company, is expected to drive its future revenue growth over the next 2-3 years through the following key initiatives:
-
Commercialization of CAN-2409 in Localized Prostate Cancer: The primary driver of future revenue growth is the anticipated commercial launch of CAN-2409 for the treatment of localized prostate cancer. Candel Therapeutics plans to submit a Biologics License Application (BLA) for CAN-2409 in this indication in the fourth quarter of 2026. If approved, this would mark the company's first commercial product, with analysts forecasting the commencement of revenue generation in 2027, significantly increasing in 2028.
-
Advancement of CAN-2409 in Non-Small Cell Lung Cancer (NSCLC): The initiation of a pivotal Phase 3 clinical trial for CAN-2409 in metastatic non-squamous non-small cell lung cancer (NSCLC) is expected in the second quarter of 2026. Positive outcomes from this late-stage trial would significantly expand the potential market for CAN-2409, increasing the asset's value and laying the groundwork for substantial future revenue growth, potentially through commercialization or strategic partnerships beyond the immediate 2-3 year horizon.
-
Strategic Collaborations and Licensing Agreements: As Candel Therapeutics progresses its lead therapeutic candidates through clinical development and toward potential commercialization, positive clinical data, particularly for CAN-2409, could lead to further strategic collaborations or out-licensing agreements. Such partnerships could generate upfront payments, milestone payments, or royalty streams, contributing to the company's revenue. Candel has already established a royalty funding agreement tied to the FDA approval of CAN-2409 in prostate cancer and a commercial collaboration for strategic input.
AI Analysis | Feedback
Share Issuance
- Candel Therapeutics completed its Initial Public Offering (IPO) in July 2021, raising $79.1 million by offering 9,000,000 shares of common stock.
- In December 2024, the company closed an underwritten public offering, generating approximately $92 million in gross proceeds from the sale of common stock and pre-funded warrants.
- Candel Therapeutics completed a follow-on equity offering in February 2026, raising approximately $100 million in gross proceeds from the issuance of 18,348,624 common shares at $5.45 per share.
Inbound Investments
- In October 2025, Candel Therapeutics secured a five-year, $130 million term loan facility with Trinity Capital Inc., with an initial $50 million drawn at closing.
- In February 2026, Candel announced a $100 million royalty funding agreement with RTW Investments, LP, contingent on FDA approval of aglatimagene in localized prostate cancer.
- As of April 2025, institutional investors held approximately 41.99% of Candel Therapeutics' shares, reflecting significant external investment in the company's equity.
Capital Expenditures
- Candel Therapeutics invested $16K in capital expenditures during fiscal year 2024.
- For Q3 2025, capital expenditures amounted to $144K.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Candel Therapeutics Earnings Notes | 12/16/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to CADL.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 3.90 |
| Mkt Cap | 0.2 |
| Rev LTM | 0 |
| Op Inc LTM | -42 |
| FCF LTM | -33 |
| FCF 3Y Avg | -30 |
| CFO LTM | -32 |
| CFO 3Y Avg | -30 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 77.3% |
| Rev Chg 3Y Avg | -98.2% |
| Rev Chg Q | 409.2% |
| QoQ Delta Rev Chg LTM | 85.8% |
| Op Mgn LTM | -4,722.1% |
| Op Mgn 3Y Avg | -13,989.4% |
| QoQ Delta Op Mgn LTM | 3,563.2% |
| CFO/Rev LTM | -3,275.9% |
| CFO/Rev 3Y Avg | -10,859.4% |
| FCF/Rev LTM | -3,279.2% |
| FCF/Rev 3Y Avg | -10,867.4% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.2 |
| P/S | 1,360.3 |
| P/EBIT | -3.0 |
| P/E | -3.0 |
| P/CFO | -4.0 |
| Total Yield | -33.6% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -32.0% |
| D/E | 0.1 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -3.1% |
| 3M Rtn | -10.0% |
| 6M Rtn | -7.7% |
| 12M Rtn | -35.2% |
| 3Y Rtn | -45.4% |
| 1M Excs Rtn | -1.3% |
| 3M Excs Rtn | -14.9% |
| 6M Excs Rtn | -8.3% |
| 12M Excs Rtn | -50.5% |
| 3Y Excs Rtn | -115.2% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Development, and potential commercialization of off-the-shelf viral immunotherapies | 0 | 0 | 0 | ||
| Total | 0 | 0 | 0 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Development, and potential commercialization of off-the-shelf viral immunotherapies | -33 | -38 | |||
| Total | -33 | -38 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Development, and potential commercialization of off-the-shelf viral immunotherapies | -55 | -38 | |||
| Total | -55 | -38 |
Price Behavior
Price Behavior
| Market Price | $5.17 | |
| Market Cap ($ Bil) | 0.3 | |
| First Trading Date | 07/27/2021 | |
| Distance from 52W High | -41.9% | |
| 50 Days | 200 Days | |
| DMA Price | $5.55 | $5.54 |
| DMA Trend | indeterminate | down |
| Distance from DMA | -6.9% | -6.7% |
| 3M | 1YR | |
| Volatility | 65.1% | 73.6% |
| Downside Capture | 209.44 | 297.53 |
| Upside Capture | 162.91 | 188.78 |
| Correlation (SPY) | 43.3% | 47.4% |
CADL Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.84 | 2.14 | 2.70 | 1.97 | 1.89 | 0.92 |
| Up Beta | 5.00 | 5.30 | 3.00 | 2.31 | 1.74 | 1.55 |
| Down Beta | 1.40 | 2.77 | 2.44 | 1.97 | 1.36 | 0.50 |
| Up Capture | 40% | 45% | 347% | 170% | 339% | 163% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 11 | 20 | 31 | 60 | 115 | 356 |
| Down Capture | 153% | 131% | 217% | 183% | 161% | 99% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 10 | 20 | 29 | 60 | 127 | 365 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CADL | |
|---|---|---|---|---|
| CADL | -41.0% | 73.6% | -0.41 | - |
| Sector ETF (XLV) | 4.6% | 17.5% | 0.11 | 35.4% |
| Equity (SPY) | 20.3% | 18.8% | 0.85 | 47.5% |
| Gold (GLD) | 68.2% | 26.2% | 1.97 | 0.4% |
| Commodities (DBC) | 19.1% | 17.3% | 0.89 | 14.3% |
| Real Estate (VNQ) | 7.6% | 16.1% | 0.27 | 29.4% |
| Bitcoin (BTCUSD) | -10.5% | 44.3% | -0.12 | 38.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CADL | |
|---|---|---|---|---|
| CADL | -5.9% | 170.2% | 0.46 | - |
| Sector ETF (XLV) | 7.3% | 14.5% | 0.32 | 5.7% |
| Equity (SPY) | 13.0% | 17.0% | 0.60 | 11.6% |
| Gold (GLD) | 23.4% | 17.2% | 1.11 | -0.1% |
| Commodities (DBC) | 11.0% | 19.0% | 0.47 | 2.2% |
| Real Estate (VNQ) | 4.8% | 18.8% | 0.16 | 5.5% |
| Bitcoin (BTCUSD) | 6.1% | 56.7% | 0.33 | 10.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CADL | |
|---|---|---|---|---|
| CADL | -3.0% | 170.2% | 0.46 | - |
| Sector ETF (XLV) | 10.2% | 16.5% | 0.50 | 5.7% |
| Equity (SPY) | 14.8% | 17.9% | 0.71 | 11.6% |
| Gold (GLD) | 14.4% | 15.6% | 0.76 | -0.1% |
| Commodities (DBC) | 8.5% | 17.6% | 0.40 | 2.2% |
| Real Estate (VNQ) | 5.8% | 20.7% | 0.24 | 5.5% |
| Bitcoin (BTCUSD) | 68.3% | 66.8% | 1.07 | 10.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/19/2026 | -14.2% | -13.4% | |
| 11/13/2025 | -6.3% | -10.2% | 17.3% |
| 8/14/2025 | -5.6% | -13.1% | -25.2% |
| 3/13/2025 | 10.2% | 3.9% | -37.4% |
| 11/14/2024 | 0.2% | -7.2% | 57.3% |
| 8/13/2024 | 4.7% | -5.9% | 18.1% |
| 3/28/2024 | 2.6% | 315.6% | 314.9% |
| 11/9/2023 | -13.0% | -2.3% | -10.0% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 7 | 6 | 7 |
| # Negative | 7 | 8 | 6 |
| Median Positive | 4.7% | 9.6% | 18.1% |
| Median Negative | -5.6% | -8.7% | -13.7% |
| Max Positive | 12.6% | 315.6% | 314.9% |
| Max Negative | -14.2% | -17.3% | -37.4% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/12/2026 | 10-K |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/13/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/28/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/30/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/05/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Nichols, William Garrett | Chief Medical Officer | Direct | Sell | 7302025 | 6.98 | 937 | 6,540 | 366,401 | Form |
| 2 | Nichols, William Garrett | Chief Medical Officer | Direct | Sell | 7022025 | 5.04 | 781 | 3,936 | 264,565 | Form |
| 3 | Nichols, William Garrett | Chief Medical Officer | Direct | Sell | 3202025 | 8.76 | 45,316 | 396,995 | 459,870 | Form |
| 4 | Barone, Francesca | Chief Scientific Officer | Direct | Sell | 3202025 | 8.76 | 32,146 | 281,673 | 845,799 | Form |
| 5 | Tak, Paul Peter | Chief Executive Officer | Direct | Sell | 3202025 | 8.77 | 25,772 | 226,023 | 1,983,270 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.